Your browser is no longer supported. Please, upgrade your browser.
Settings
MTEM Molecular Templates, Inc. daily Stock Chart
MTEM [NASD]
Molecular Templates, Inc.
Index- P/E- EPS (ttm)-1.50 Insider Own5.41% Shs Outstand6.95M Perf Week-5.35%
Market Cap44.27M Forward P/E- EPS next Y-0.78 Insider Trans0.00% Shs Float6.16M Perf Month25.15%
Income-13.30M PEG- EPS next Q-0.15 Inst Own28.70% Short Float2.31% Perf Quarter41.24%
Sales3.00M P/S14.76 EPS this Y-156.50% Inst Trans-10.98% Short Ratio1.59 Perf Half Y4.02%
Book/sh0.24 P/B26.54 EPS next Y40.90% ROA-56.20% Target Price10.50 Perf Year-54.40%
Cash/sh2.42 P/C2.64 EPS next 5Y- ROE-70.90% 52W Range3.85 - 14.52 Perf YTD31.31%
Dividend- P/FCF- EPS past 5Y9.60% ROI- 52W High-56.13% Beta3.28
Dividend %- Quick Ratio8.40 Sales past 5Y- Gross Margin- 52W Low65.45% ATR0.45
Employees15 Current Ratio8.40 Sales Q/Q239.70% Oper. Margin- RSI (14)55.76 Volatility7.45% 7.14%
OptionableNo Debt/Eq0.00 EPS Q/Q101.50% Profit Margin- Rel Volume0.61 Prev Close6.24
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume89.64K Price6.37
Recom2.00 SMA205.21% SMA5011.50% SMA20012.70% Volume54,795 Change2.08%
Sep-06-17 02:17PM  Molecular Templates to Present at the BioCentury 24th Annual Newsmakers in the Biotech Industry Conference GlobeNewswire
Sep-05-17 12:41PM  5 of the Best Stocks Under $10 for 2017 Zacks +5.13%
Aug-31-17 10:10AM  Molecular Templates, Inc. (Nasdaq: MTEM) to Ring the Nasdaq Stock Market Closing Bell GlobeNewswire +6.86%
Aug-30-17 08:30AM  Molecular Templates to Ring NASDAQ Closing Bell Friday, September 1, 2017 GlobeNewswire
Aug-14-17 08:00AM  Molecular Templates to Present at the 2017 Wedbush PacGrow Healthcare Conference GlobeNewswire -9.86%
Aug-10-17 08:00AM  Molecular Templates Potential Catalysts, Merger Synergies and Pipeline Review ACCESSWIRE
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is headquartered in Austin, Texas.